Daewoong Pharmaceutical is launching the 'Daewoong Alliance' in collaboration with 12 domestic digital healthcare companies.
The company announced on August 19 that it will showcase the Daewoong Alliance at the 'Korea Hospital and Health Tech Fair (KHF) 2026,' taking place at COEX in Seoul until August 21.
The Daewoong Alliance is a digital healthcare collaboration model that connects health data generated in hospitals and daily life, extending beyond drug-centered treatment to encompass prevention, diagnosis, treatment, and post-care. Daewoong Pharmaceutical plans to build a healthcare ecosystem based on the '4P paradigm,' which stands for prevention, prediction, precision, and participation.
At the event, Daewoong Pharmaceutical will operate a joint exhibition space with 12 partner companies, including Cears, Skylabs, Medical AI, Arc, TR, Puzzle AI, iCoop, Promedius, Everex, AllSoCare, Hurotics, and Exosystems, featuring around 20 booths. The exhibition will be located in the COEX G30 area.
The partner companies will demonstrate solutions in various fields, including diagnostics, monitoring, chronic disease management, digital therapy, and medical artificial intelligence (AI). Daewoong Pharmaceutical will host a total of 34 expert lectures over three days, sharing the clinical value of each technology and real-world application cases. Discussions on specific commercialization strategies with hospital representatives will also take place.
Daewoong Pharmaceutical aims to leverage its sales and marketing infrastructure in conjunction with the technological capabilities of its partners to position the Daewoong Alliance as a key growth driver in the digital healthcare sector.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "We will establish a total healthcare environment that encompasses disease prediction to post-care based on data."
In the first half of this year alone, Daewoong Pharmaceutical invested approximately 7.4 billion won in six companies, expanding its investment areas to include medical AI, data, imaging diagnostics, medical devices, and next-generation therapeutics.
The market views this strategy as a proactive approach to securing technologies and products that can synergize with existing pharmaceutical operations, beyond simple equity investments, as well as next-generation pipelines.
The company announced on August 19 that it will showcase the Daewoong Alliance at the 'Korea Hospital and Health Tech Fair (KHF) 2026,' taking place at COEX in Seoul until August 21.
The Daewoong Alliance is a digital healthcare collaboration model that connects health data generated in hospitals and daily life, extending beyond drug-centered treatment to encompass prevention, diagnosis, treatment, and post-care. Daewoong Pharmaceutical plans to build a healthcare ecosystem based on the '4P paradigm,' which stands for prevention, prediction, precision, and participation.
At the event, Daewoong Pharmaceutical will operate a joint exhibition space with 12 partner companies, including Cears, Skylabs, Medical AI, Arc, TR, Puzzle AI, iCoop, Promedius, Everex, AllSoCare, Hurotics, and Exosystems, featuring around 20 booths. The exhibition will be located in the COEX G30 area.
The partner companies will demonstrate solutions in various fields, including diagnostics, monitoring, chronic disease management, digital therapy, and medical artificial intelligence (AI). Daewoong Pharmaceutical will host a total of 34 expert lectures over three days, sharing the clinical value of each technology and real-world application cases. Discussions on specific commercialization strategies with hospital representatives will also take place.
Daewoong Pharmaceutical aims to leverage its sales and marketing infrastructure in conjunction with the technological capabilities of its partners to position the Daewoong Alliance as a key growth driver in the digital healthcare sector.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "We will establish a total healthcare environment that encompasses disease prediction to post-care based on data."
In the first half of this year alone, Daewoong Pharmaceutical invested approximately 7.4 billion won in six companies, expanding its investment areas to include medical AI, data, imaging diagnostics, medical devices, and next-generation therapeutics.
The market views this strategy as a proactive approach to securing technologies and products that can synergize with existing pharmaceutical operations, beyond simple equity investments, as well as next-generation pipelines.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.